- |||||||||| colesevelam / Generic mfg.
Journal: The Effect of Colesevelam on the Microbiome in Postoperative Crohn's Disease. (Pubmed Central) - Oct 18, 2024 Furthermore, treatment with colesevelam may have a role in altering the microbiome to help maintain remission states in postoperative Crohn's disease. Larger mechanistic studies are now needed to confirm these findings and demonstrate statistical significance as well as investigate whether this benefit may be present even in those patients with 75SeHCAT negative disease.
- |||||||||| Remicade (infliximab) / J&J, Entyvio (vedolizumab) / Takeda, Humira (adalimumab) / AbbVie
Review, Journal: Microscopic Colitis: An Underestimated Disease of Growing Importance. (Pubmed Central) - Oct 16, 2024 Treatment consists of budesonide oral (the gold standard) or enema. Alternatives include bile acid sequestrants (cholestyramine, colesevelam, and colestipol), biologics (infliximab, adalimumab, and vedolizumab), thiopurines, methotrexate, and rarely, surgery.
- |||||||||| Victoza (liraglutide) / Novo Nordisk
Clinical, Journal: Liraglutide and Colesevelam Changes Serum and Fecal Bile Acid Levels in a Randomized Trial with Patients with Bile Acid Diarrhea. (Pubmed Central) - Sep 23, 2024 Alternatives include bile acid sequestrants (cholestyramine, colesevelam, and colestipol), biologics (infliximab, adalimumab, and vedolizumab), thiopurines, methotrexate, and rarely, surgery. Colesevelam and liraglutide exhibit distinct effects on serum and fecal bile acid concentrations with colesevelam reducing serum concentrations of secondary bile acids and promoting fecal bile acid excretion while liraglutide enhances serum concentrations of unconjugated bile acids, potentially through deceleration of small intestinal transit time allowing more time for passive absorption of bile acids.
- |||||||||| lenalidomide / Generic mfg., colesevelam / Generic mfg.
Journal: Colesevelam for lenalidomide associated diarrhea in patients with multiple myeloma. (Pubmed Central) - Sep 21, 2024 Colesevelam and liraglutide exhibit distinct effects on serum and fecal bile acid concentrations with colesevelam reducing serum concentrations of secondary bile acids and promoting fecal bile acid excretion while liraglutide enhances serum concentrations of unconjugated bile acids, potentially through deceleration of small intestinal transit time allowing more time for passive absorption of bile acids. No abstract available
- |||||||||| Review, Journal: Managing bile acid diarrhea: aspects of contention. (Pubmed Central) - Sep 12, 2024
They are relatively inexpensive, and better-quality data is now available for colesevelam...The GLP-1 receptor agonist, liraglutide, is also effective, although mechanisms of action and whether this effect is common to other class members is unclear...The role of dietary factors in symptom development is a major patient concern, needing more formal studies. To build on recent findings, bile acid diarrhea needs further investment into causes, diagnosis and therapy to guide present and future patient care.
- |||||||||| Stelara (ustekinumab) / J&J
Treatment of Refractory CVID Enteropathy With Ustekinumab (Exhibit Hall E) - Aug 20, 2024 - Abstract #ACG2024ACG_1487; In this case, multiple therapies including infliximab and vedolizumab failed to produce clinical response, while treatment with ustekinumab has resulted in clinical remission and significant reduction in fecal calprotectin. Notably, while infliximab and vedolizumab treatment were associated with recurrent pulmonary infections in this patient, she has had a significant decrease in infections while on ustekinumab.
- |||||||||| colesevelam / Generic mfg.
PEPTIDE TYROSINE TYROSINE IS INCREASED IN INDIVIDUALS WITH BILE ACID DIARRHOEA (Science Lounge) - Jul 18, 2024 - Abstract #UEGW2024UEGW_371; Here, we demonstrate elevated fasting PYY levels, but normal postprandial PYY responses in individuals with BAD compared to carefully matched healthy controls supporting the notion that bile acids in the gut lumen stimulates the secretion of PYY in individuals with BAD. Whether and how elevated PYY levels contribute to or might counteract BAD pathophysiology remains uncertain.
- |||||||||| lenalidomide / Generic mfg., colesevelam / Generic mfg.
Trial completion date, Trial primary completion date: A Study of Colesevelam for Lenalidomide-Associated Diarrhea (clinicaltrials.gov) - Jul 2, 2024 P2, N=25, Active, not recruiting, Whether and how elevated PYY levels contribute to or might counteract BAD pathophysiology remains uncertain. Trial completion date: Jun 2024 --> Jun 2025 | Trial primary completion date: Jun 2024 --> Jun 2025
- |||||||||| lenalidomide / Generic mfg., colesevelam / Generic mfg.
Journal: Colesevelam for Lenalidomide Associated Diarrhea in Patients with Multiple Myeloma. (Pubmed Central) - Jun 17, 2024 Patients reported improved diarrhea, fewer gastrointestinal symptoms, and less interference with their daily life after starting colesevelam. In summary, colesevelam was safe and highly effective for treatment of lenalidomide-associated diarrhea in multiple myeloma and does not reduce the clinical effect of lenalidomide.
- |||||||||| colesevelam / Generic mfg.
Journal: Colesevelam has no acute effect on postprandial GLP-1 levels but abolishes gallbladder refilling. (Pubmed Central) - Apr 18, 2024 Single-dose colesevelam had no effect on postprandial GLP-1 responses or glucose tolerance but disrupted postprandial gallbladder refilling by increasing CCK secretion and reducing circulating concentrations of FGF19 and bile acids. These findings leave the antidiabetic actions of colesevelam unresolved but provide mechanistic insights into its effect on gallbladder motility.
- |||||||||| cholestyramine (A3384) / Ipsen
It might not be the enzymes! A single centre experience of investigating bile acid malabsorption (Hall 1) - Mar 22, 2024 - Abstract #ECFS2024ECFS_71; Adults with CF and significant abdominal symptoms should be referred for SeHCAT once more common causes of symptoms have been excluded. This includes those who are pancreatic sufficient or those who are PI and continue to experience abdominal symptoms despite PERT optimisation.?In response to more adult patients experiencing gastrointestinal symptoms, we have incorporated an abdominal symptom pathway into our dietetic annual review.
- |||||||||| Praluent (alirocumab) / Sanofi, Regeneron, Repatha (evolocumab) / Amgen, Astellas
Trial completion date, Trial primary completion date: PERI-DYS: Prospective German Very High Cardiovascular Risk Patients Dyslipidemia Treatment Indication Registry (clinicaltrials.gov) - Feb 22, 2024 P=N/A, N=1713, Active, not recruiting, Additionally, patients with MC and BAM were more likely to respond to BAS therapy, supporting the utility of bile acid testing in predicting response to treatment. Trial completion date: Dec 2023 --> Jun 2024 | Trial primary completion date: Dec 2023 --> Mar 2024
- |||||||||| colesevelam / Generic mfg., bromocriptine / Generic mfg.
Review, Journal: Bromocriptine and Colesevelam Hydrochloride: Novel Therapies for Type II Diabetes Mellitus. (Pubmed Central) - Jan 9, 2024 In order to ensure that these overlooked medications become more readily used, it is vital that more research be performed to further elucidate their efficacy in a clinical setting. Future studies should continue to provide clinicians a better understanding of the role these medications have on the treatment of T2DM such as their ability to be used in combination with other commonly used T2DM medications or as monotherapies.
- |||||||||| cholestyramine (A3384) / Ipsen
Journal: The Epidemiology of Bile Acid Diarrhea in Denmark. (Pubmed Central) - Dec 13, 2023 The BAD population had more co-morbidities and more health care contacts as well as lower levels of education and income compared with age- and sex-matched controls from the general population. Using the Danish registries, we identified a BAD population, which seems to be inferior in health care and socio-economic parameters compared with the Danish general population.
- |||||||||| loperamide / Generic mfg., colesevelam / Generic mfg.
Review, Journal: Clinical Management of Low Anterior Resection Syndrome: Review of the Current Diagnosis and Treatment. (Pubmed Central) - Oct 28, 2023 Moreover, a new scale needs to be developed to incorporate the patient's perspective and facilitate outpatient follow-up. Though the establishment of a stepwise classification model for LARS treatment here is indispensable, the refinement of the guidelines may be improved by more standardized studies.
- |||||||||| clonidine / Generic mfg., colesevelam / Generic mfg.
Journal: A randomized double-blind trial of clonidine and colesevelam for women with fecal incontinence. (Pubmed Central) - Oct 27, 2023 Though the establishment of a stepwise classification model for LARS treatment here is indispensable, the refinement of the guidelines may be improved by more standardized studies. Compared with placebo, clonidine-colesevelam did not significantly improve FI despite being associated with more formed stools and fewer FI episodes for semiformed stools.
- |||||||||| Victoza (liraglutide) / Novo Nordisk
Journal: New Developments in Bile Acid Diarrhea. (Pubmed Central) - Sep 29, 2023 Novel experimental approaches for BAD include farnesoid X receptor agonists and fibroblast growth factor 19 analogs. This article updates information on the pathophysiology, mechanisms, manifestations, diagnosis, and treatment of BAD.
- |||||||||| Cholebine (colestilan) / Mitsubishi Tanabe
Review, Journal: Bile Acid Sequestrants Based on Natural and Synthetic Gels. (Pubmed Central) - Jun 27, 2023 Focus is given to the understanding of the relationships between the chemical structure of these cross-linked polymers and their potential to bind bile salts. The synthetic pathways used in obtaining BASs and their in vitro and in vivo hypolipidemic activities are also introduced.
- |||||||||| clonidine / Generic mfg., colesevelam / Generic mfg.
A DOUBLE-BLIND PLACEBO CONTROLLED STUDY OF CLONIDINE AND COLESEVELAM FOR FECAL INCONTINENCE (FI) (S105a - McCormick Place) - Mar 23, 2023 - Abstract #DDW2023DDW_7201; CC but not placebo was more effective in pts with a higher rectal sensory threshold volume for urgency, which suggests that is more likely to be effective in pts without rectal hypersensitivity. Future controlled trials should evaluate the utility of CC in patients who have documented bile acid malabsorption.
- |||||||||| colesevelam / Generic mfg.
IS COLESEVELAM EFFECTIVE? (W194 - McCormick Place) - Mar 23, 2023 - Abstract #DDW2023DDW_1695;
- |||||||||| colesevelam / Generic mfg.
Journal: Lessons from a trial of colesevelam for bile acid diarrhoea. (Pubmed Central) - Mar 14, 2023 This data provides reassurance that the beneficial clinical effects of BA sequestrant treatment do not exert a negative effect on microbiome diversity in patients with CD. No abstract available
- |||||||||| Procoralan (ivabradine) / Amgen, Servier, Ono Pharma
Journal: Impact of the COVID-19 pandemic on cardiovascular heart disease medication use: time-series analysis of England's prescription data during the COVID-19 pandemic (January 2019 to October 2020). (Pubmed Central) - Nov 25, 2022 After the pandemic began (March-October 2020), negative parameters are observed for ACE inhibitors, beta-blockers, calcium channel blockers, statins, antiplatelet, antithrombotics, ARBs, loop diuretics, doxazosin, bendroflumethiazide, nitrates and indapamide, indicating decelerating monthly prescription items (statistically significant declines of calcium channel blockers, antithrombotic, adrenoreceptor blockers and diuretics) of CVD medicines within the general population...Accessible screening and treatment alongside financial relief on prescription levies are needed. A video abstract is (4 min 51 s) available: https://bit.ly/39gvEHi.
- |||||||||| lenalidomide / Generic mfg., colesevelam / Generic mfg.
A Phase 2 Trial of Colesevelam for Lenalidomide-Associated Diarrhea (ENMCC - Hall D) - Nov 4, 2022 - Abstract #ASH2022ASH_2806; Conclusion In this prospective, single arm clinical trial, colesevelam was safe and highly effective for the control of lenalidomide-associated diarrhea in multiple myeloma patients receiving single agent lenalidomide maintenance. Lenalidomide PK and stool microbiome studies are ongoing and will be reported at the ASH Annual Meeting 2022.
|